A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convectionenhanced delivery for adult patients with recurrent malignant glioma (MG)

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2022
This article has no abstract
Epistemonikos ID: ba5568eb637af4054f9a63a97855f8b0f84b9d48
First added on: Feb 14, 2025